Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for Cyclin E-overexpressing cancers IND for APR-1051 has been cleared; details on planned Phase 1 first in human trial (ACESOT-1051) presented

First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024 U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase 1 ACESOT-1051

Financing led by Sphera Healthcare with participation from new and existing healthcare-focused institutional investors $16.0 million in upfront gross proceeds with the potential to receive up to an additional $18.0 million in potential warrant exercise proceeds for an aggregate of up to $34.0

Company plans to initiate Phase 1 ACESOT-1051 ( A Multi- C enter E valuation of WEE1 Inhibitor in Patients with Advanced So lid T umors, APR- 1051 )   clinical trial evaluating , highly selective, oral WEE1 inhibitor, for monotherapy treatment of Cyclin E overexpressing cancers including breast and

Four Poster Presentations, Including Posters on ATRN-119 (novel macrocyclic ATR inhibitor) and APR-1051 (next generation WEE1 kinase inhibitor) DOYLESTOWN, Pa. , March 05, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical-stage

DOYLESTOWN, Pa. , Feb. 06, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has submitted an Investigational New Drug (IND)

DOYLESTOWN, Pa. , Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Dr. Oren Gilad , President and CEO, will deliver a

DOYLESTOWN, Pa. , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today provided a corporate update highlighting recent developments and

DOYLESTOWN, Pa. , Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and nine months ended

Event featuring Fiona Simpkins, M.D. and Timothy A. Yap, MBBS, PhD, FRCP to take place on October 31, 2023 at 11:00 am ET DOYLESTOWN, Pa. , Oct. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on